{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:23:52Z","timestamp":1787837032181,"version":"build-2784847793"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glioblastoma (GBM) is characterized by high invasiveness and metabolic heterogeneity. Protein Tyrosine Phosphatase Receptor Type Z1 (PTPRZ1) has been implicated in glioma stemness and tumor grade progression, while the molecular mechanism remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Integrated bioinformatics analysis of TCGA dataset and TMA IHC profiling were used to explore clinical relevance of PTPRZ1, and potential molecular mechanisms of PTPRZ1 involved glioma progression. Ivy Glioblastoma datasets analysis and multiregional GBM IHC were performed to spatially characterize the expression patterns of PTPRZ1 in GBM tissues. Zebrafish xenograft model was established to elucidate the role of PTPRZ1 in driving glioblastoma cell migration. Western blotting, mitochondrial functional assays, Transwell migration assays, and human GBM tissue multiplexing were employed to investigate the mechanism of PTPRZ1 mediated glioma cell mobility via maintaining mitochondrial functions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Spatial profiling revealed that PTPRZ1 is significantly enriched in the infiltrating areas and peritumoral margins of GBM, and acts as a poor prognosis factor in lower grade astrocytoma, proneural and mesenchymal GBM. Mechanistically, PTPRZ1 expression was found to be strongly correlated with cell adhesion molecules (CAMs) and mitochondrial metabolism across multiple glioma subtypes. Knockdown of PTPRZ1 triggered a shift from elongated to fragmented mitochondrial morphology by specifically downregulating the mitochondrial fusion protein OPA1. This mitochondrial dysfunction led to a metabolic shift toward glycolysis and a marked accumulation of ROS, which suppressed N-cadherin expression, thereby impairing glioma cell migration. These findings were corroborated in vivo, where PTPRZ1 depletion significantly reduced disseminated tumor foci in a zebrafish model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study demonstrates that PTPRZ1 drives glioblastoma migration by sustaining an OPA1-dependent mitochondrial fusion program, which suppresses mitochondrial ROS levels and subsequently stabilizes a pro-migratory phenotype via N-cadherin expression. Targeting the PTPRZ1\/OPA1\/ROS axis represents a promising therapeutic strategy to inhibit the invasive expansion of GBM cells.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-08884-7","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:14:39Z","timestamp":1787760879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Spatial enrichment of PTPRZ1 in the peritumoral niche drives glioblastoma migration via the OPA1\/ROS\/CDH2 axis"],"prefix":"10.1186","volume":"24","author":[{"given":"Li","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiquan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"\u00d6stman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"issue":"1","key":"8884_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40169-019-0253-6","volume":"8","author":"E Skaga","year":"2019","unstructured":"Skaga E, Kulesskiy E, Brynjulvsen M, Sandberg CJ, Potdar S, Langmoen IA, et al. Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment. Clin Transl Med. 2019;8(1):33.","journal-title":"Clin Transl Med"},{"issue":"2","key":"8884_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","volume":"114","author":"DN Louis","year":"2007","unstructured":"Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97\u2013109.","journal-title":"Acta Neuropathol"},{"issue":"7","key":"8884_CR3","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/(SICI)1097-0142(19970401)79:7<1381::AID-CNCR16>3.0.CO;2-W","volume":"79","author":"SW Coons","year":"1997","unstructured":"Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer. 1997;79(7):1381\u201393.","journal-title":"Cancer"},{"issue":"3","key":"8884_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4103\/glioma.glioma_13_18","volume":"1","author":"L Yi","year":"2018","unstructured":"Yi L, Ming H, Yu S, Ren B, Yang X. Ongoing evolution of response assessment in glioma: Where do we stand? Glioma. 2018;1(3):97\u2013103.","journal-title":"Glioma"},{"issue":"1","key":"8884_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RG Verhaak","year":"2010","unstructured":"Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98\u2013110.","journal-title":"Cancer Cell"},{"issue":"3","key":"8884_CR6","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","volume":"164","author":"M Ceccarelli","year":"2016","unstructured":"Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016;164(3):550\u201363.","journal-title":"Cell"},{"issue":"2","key":"8884_CR7","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462\u201377.","journal-title":"Cell"},{"issue":"6","key":"8884_CR8","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803\u201320.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"8884_CR9","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1186\/s40169-018-0211-8","volume":"7","author":"D Ghosh","year":"2018","unstructured":"Ghosh D, Nandi S, Bhattacharjee S. Combination therapy to checkmate Glioblastoma: clinical challenges and advances. Clin Translational Med. 2018;7(1):e33.","journal-title":"Clin Translational Med"},{"issue":"6","key":"8884_CR10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00401-008-0455-2","volume":"116","author":"J Balss","year":"2008","unstructured":"Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116(6):597\u2013602.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"8884_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40478-016-0372-x","volume":"4","author":"AM Bourgonje","year":"2016","unstructured":"Bourgonje AM, Verrijp K, Schepens JTG, Navis AC, Piepers JAF, Palmen CBC, et al. Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma. Acta Neuropathol Commun. 2016;4(1):96.","journal-title":"Acta Neuropathol Commun"},{"key":"8884_CR12","doi-asserted-by":"crossref","unstructured":"Zhao H, Wang Y, Yang C, Zhou J, Wang L, Yi K, et al. EGFR-vIII downregulated H2AZK4\/7AC through the PI3K\/AKT-HDAC2 axis to regulate cell cycle progression. Clin Translational Med. 2020;9(1):10.","DOI":"10.1186\/s40169-020-0260-7"},{"issue":"5","key":"8884_CR13","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.ccell.2017.09.014","volume":"32","author":"M Pathania","year":"2017","unstructured":"Pathania M, De Jay N, Maestro N, Harutyunyan AS, Nitarska J, Pahlavan P, et al. H3.3(K27M) Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas. Cancer Cell. 2017;32(5):684\u2013e7009.","journal-title":"Cancer Cell"},{"issue":"1","key":"8884_CR14","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s13046-019-1269-x","volume":"38","author":"F Cheng","year":"2019","unstructured":"Cheng F, Guo D. MET in glioma: signaling pathways and targeted therapies. J Exp Clin Cancer Res. 2019;38(1):270.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"8884_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00401-015-1420-5","volume":"130","author":"AC Navis","year":"2015","unstructured":"Navis AC, Lith SAMV, Duijnhoven SMJV, Pooter MD, Yetkin-Arik B, Wesseling P, et al. Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein. Acta Neuropathol. 2015;130(1):131\u201344.","journal-title":"Acta Neuropathol"},{"key":"8884_CR16","doi-asserted-by":"crossref","unstructured":"J?Ger R, List B, Knabbe ., Souttou C, Raulais B, Zeiler D. Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients. Br J Cancer. 2002;86(6):858\u201363.","DOI":"10.1038\/sj.bjc.6600202"},{"issue":"2","key":"8884_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0304-3835(03)00450-6","volume":"204","author":"K Kadomatsu","year":"2004","unstructured":"Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett. 2004;204(2):127\u201343.","journal-title":"Cancer Lett"},{"issue":"6","key":"8884_CR18","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.2353\/ajpath.2007.070741","volume":"171","author":"YT Liu","year":"2007","unstructured":"Liu YT, Shang D, Akatsuka S, Ohara H, Dutta KK, Mizushima K, et al. Chronic Oxidative Stress Causes Amplification and Overexpression of ptprz1 Protein Tyrosine Phosphatase to Activate \u03b2-Catenin Pathway. Am J Pathol. 2007;171(6):1978\u201388.","journal-title":"Am J Pathol"},{"issue":"1","key":"8884_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.neulet.2006.01.045","volume":"399","author":"H Tamura","year":"2006","unstructured":"Tamura H, Fukada M, Fujikawa A, Noda M. Protein tyrosine phosphatase receptor type Z is involved in hippocampus-dependent memory formation through dephosphorylation at Y1105 on p190 RhoGAP. Neurosci Lett. 2006;399(1):33\u20138.","journal-title":"Neurosci Lett"},{"key":"8884_CR20","doi-asserted-by":"crossref","unstructured":"Meng K, Rodriguez-Pe?A A, ., Dimitrov T, Chen .,. W, Yamin M, Noda . Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta\/zeta. Proc Natl Acad Sci USA. 2000;97(6):2603\u20138.","DOI":"10.1073\/pnas.020487997"},{"key":"8884_CR21","doi-asserted-by":"crossref","unstructured":"Ma L, Shen T, Peng H, Wu J, Wang W, Gao X. Overexpression of PTPRZ1 regulates p120\/\u03b2-catenin phosphorylation to promote carcinogenesis of oral submucous fibrosis. J Oncol. 2022;2022:2352360.","DOI":"10.1155\/2022\/2352360"},{"issue":"43","key":"8884_CR22","doi-asserted-by":"publisher","first-page":"15066","DOI":"10.1523\/JNEUROSCI.1320-12.2012","volume":"32","author":"CR McClain","year":"2012","unstructured":"McClain CR, Sim FJ, Goldman SA. Pleiotrophin suppression of receptor protein tyrosine phosphatase-beta\/zeta maintains the self-renewal competence of fetal human oligodendrocyte progenitor cells. J neuroscience: official J Soc Neurosci. 2012;32(43):15066\u201375.","journal-title":"J neuroscience: official J Soc Neurosci"},{"key":"8884_CR23","doi-asserted-by":"crossref","unstructured":"Kuboyama K, Fujikawa A, Suzuki R, Noda M. Inactivation of protein tyrosine phosphatase receptor type Z by pleiotrophin promotes remyelination through activation of differentiation of oligodendrocyte precursor cells. J Neurosci. 2015;35(35):12162-71.","DOI":"10.1523\/JNEUROSCI.2127-15.2015"},{"key":"8884_CR24","doi-asserted-by":"crossref","unstructured":"Shi Y, Ping YF, Zhou W, He ZC, Chen C, Bian BSJ, et al. Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth. Nat Commun. 2017;8:15080.","DOI":"10.1038\/ncomms15080"},{"issue":"5","key":"8884_CR25","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.cell.2017.07.016","volume":"170","author":"EY Qin","year":"2017","unstructured":"Qin EY, Cooper DD, Abbott KL, Lennon J, Nagaraja S, Mackay A, et al. Neural Precursor-Derived Pleiotrophin Mediates Subventricular Zone Invasion by Glioma. Cell. 2017;170(5):845\u201359.","journal-title":"Cell"},{"issue":"1","key":"8884_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.stem.2019.11.015","volume":"26","author":"A Bhaduri","year":"2020","unstructured":"Bhaduri A, Di Lullo E, Jung D, M\u00fcller S, Crouch EE, Espinosa CS, et al. Outer Radial Glia-like Cancer Stem Cells Contribute to Heterogeneity of Glioblastoma. Cell Stem Cell. 2020;26(1):48\u2013e636.","journal-title":"Cell Stem Cell"},{"issue":"38","key":"8884_CR27","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.1038\/onc.2017.134","volume":"36","author":"AL Zeng","year":"2017","unstructured":"Zeng AL, Yan W, Liu YW, Wang Z, Hu Q, Nie E, et al. Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma. Oncogene. 2017;36(38):5369\u201381.","journal-title":"Oncogene"},{"issue":"11","key":"8884_CR28","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1101\/gr.165126.113","volume":"24","author":"ZS Bao","year":"2014","unstructured":"Bao ZS, Chen HM, Yang MY, Zhang CB, Yu K, Ye WL, et al. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Res. 2014;24(11):1765\u201373.","journal-title":"Genome Res"},{"issue":"11","key":"8884_CR29","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/nm.4204","volume":"22","author":"Recurrent","year":"2016","unstructured":"Recurrent. MET fusion genes represent a drug target in pediatric glioblastoma. Nat Med. 2016;22(11):1314\u201320.","journal-title":"Nat Med"},{"key":"8884_CR30","doi-asserted-by":"crossref","unstructured":"Huang R, Liu Y, Wang K. High-sensitive clinical diagnostic method for PTPRZ1-MET and the characteristic protein structure contributing to ligand-independent MET activation. CNS Neurosci Ther. 2021;27(5):617-28.","DOI":"10.1111\/cns.13627"},{"issue":"n\/a","key":"8884_CR31","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1002\/ctm2.130","volume":"n\/a","author":"L Yi","year":"2020","unstructured":"Yi L, Guo G, Li J, Fan X, Li T, Tong L, et al. IKBKE, a prognostic factor preferentially expressed in mesenchymal glioblastoma, modulates tumoral immunosuppression through the STAT3\/PD-L1 pathway. Clin Translational Med. 2020;n\/a(n\/a):e130.","journal-title":"Clin Translational Med"},{"issue":"1","key":"8884_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/ijc.25647","volume":"129","author":"M Ferletta","year":"2011","unstructured":"Ferletta M, Caglayan D, Mokvist L, Jiang Y, Kastemar M, Uhrbom L, et al. Forced expression of Sox21 inhibits Sox2 and induces apoptosis in human glioma cells. Int J Cancer. 2011;129(1):45\u201360.","journal-title":"Int J Cancer"},{"key":"8884_CR33","doi-asserted-by":"crossref","unstructured":"Goudarzi KM, Espinoza JA. Reduced expression of PROX1 transitions glioblastoma cells into a mesenchymal gene expression subtype. Cancer Res. 2018;78(20):5901-16.","DOI":"10.1158\/0008-5472.CAN-18-0320"},{"key":"8884_CR34","doi-asserted-by":"crossref","unstructured":"Guo M, van Vliet M, Zhao J, St\u00e5hl TD, Lindstr\u00f6m MS, Cheng H, et al. Identification of functionally distinct and interacting cancer cell subpopulations from a glioblastoma with intratumoral genetic heterogeneity. Neuro Oncol Adv. 2020;2(1):vdaa061.","DOI":"10.1093\/noajnl\/vdaa061"},{"issue":"1","key":"8884_CR35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s13046-019-1319-4","volume":"38","author":"L Yi","year":"2019","unstructured":"Yi L, Zhou X, Li T, Liu P, Hai L, Tong L, et al. Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12\/CXCR4. J Experimental Clin Cancer Res. 2019;38(1):339.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"1","key":"8884_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10238-025-01631-0","volume":"25","author":"MS Anwer","year":"2025","unstructured":"Anwer MS, Abdel-Rasol MA, El-Sayed WM. Emerging therapeutic strategies in glioblastsoma: drug repurposing, mechanisms of resistance, precision medicine, and technological innovations. Clin Experimental Med. 2025;25(1):117.","journal-title":"Clin Experimental Med"},{"key":"8884_CR37","doi-asserted-by":"publisher","first-page":"111191","DOI":"10.1016\/j.cellsig.2024.111191","volume":"120","author":"Y Wang","year":"2024","unstructured":"Wang Y, Suo J, Wang Z, Ran K, Tian Y, Han W, et al. The PTPRZ1-MET\/STAT3\/ISG20 axis in glioma stem-like cells modulates tumor-associated macrophage polarization. Cell Signal. 2024;120:111191.","journal-title":"Cell Signal"},{"issue":"1","key":"8884_CR38","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ccell.2017.06.003","volume":"32","author":"Q Wang","year":"2017","unstructured":"Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, et al. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell. 2017;32(1):42\u2013e566.","journal-title":"Cancer Cell"},{"issue":"7","key":"8884_CR39","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1016\/j.ymthe.2021.10.028","volume":"30","author":"Z Chen","year":"2022","unstructured":"Chen Z, Wang S, Li HL, Luo H, Wu X, Lu J, et al. FOSL1 promotes proneural-to-mesenchymal transition of glioblastoma stem cells via UBC9\/CYLD\/NF-\u03baB axis. Mol therapy: J Am Soc Gene Therapy. 2022;30(7):2568\u201383.","journal-title":"Mol therapy: J Am Soc Gene Therapy"},{"issue":"45","key":"8884_CR40","doi-asserted-by":"publisher","first-page":"7089","DOI":"10.1038\/s41388-019-0949-5","volume":"38","author":"Y Han","year":"2019","unstructured":"Han Y, Kim B, Cho U, Park IS, Kim SI, Dhanasekaran DN, et al. Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells. Oncogene. 2019;38(45):7089\u2013105.","journal-title":"Oncogene"},{"key":"8884_CR41","doi-asserted-by":"crossref","unstructured":"Goliwas KF, Libring S, Berestesky E, Gholizadeh S, Schwager SC, Frost AR, et al. Mitochondrial transfer from cancer-associated fibroblasts increases migration in aggressive breast cancer. J Cell Sci. 2023;136(14):jcs260419.","DOI":"10.1242\/jcs.260419"},{"key":"8884_CR42","doi-asserted-by":"publisher","first-page":"103302","DOI":"10.1016\/j.redox.2024.103302","volume":"75","author":"B Sun","year":"2024","unstructured":"Sun B, Ding P, Song Y, Zhou J, Chen X, Peng C, et al. FDX1 downregulation activates mitophagy and the PI3K\/AKT signaling pathway to promote hepatocellular carcinoma progression by inducing ROS production. Redox Biol. 2024;75:103302.","journal-title":"Redox Biol"},{"key":"8884_CR43","doi-asserted-by":"publisher","first-page":"103288","DOI":"10.1016\/j.redox.2024.103288","volume":"75","author":"P Vaishampayan","year":"2024","unstructured":"Vaishampayan P, Lee Y. Redox-active vitamin C suppresses human osteosarcoma growth by triggering intracellular ROS-iron-calcium signaling crosstalk and mitochondrial dysfunction. Redox Biol. 2024;75:103288.","journal-title":"Redox Biol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08884-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08884-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08884-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:10:20Z","timestamp":1787836220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08884-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8884"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08884-7","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"19 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study strictly adhered to the ethical principles of the Declaration of Helsinki and was approved by the Medical Ethics Committee of Tianjin Medical University General Hospital (March 03, 2018). All zebrafish work was performed according to the regulations by the Karolinska Institutet Zebrafish Core Facility, which holds ethical permits from the Stockholm Prefecture Ethics Committee.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors approved the manuscript for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1103"}}